Pharmacology of Anemia and Hematopoietic Growth Factors Flashcards Preview

Skin, Blood & Lymph Exam #1 > Pharmacology of Anemia and Hematopoietic Growth Factors > Flashcards

Flashcards in Pharmacology of Anemia and Hematopoietic Growth Factors Deck (27)
Loading flashcards...
1
Q

What are some causes of microcytic anemia?

What is the MCV?

A

Reduced iron availability (most common)
Reduced heme synthesis
Reduced globin production

MCV < 80 fL

2
Q

What are some side-effects of oral iron supplementation?

A

Nausea, constipation, anorexia, heartburn, vomiting, diarrhea and dark stools.

3
Q

What is the dosage and frequency for oral iron?

A

200-400 mg of ferrous iron 2-3x/day.

4
Q

What form of iron is used in supplementation/treatment?

A

Ferrous iron (2+)

5
Q

Under what conditions would parenteral iron be preferred to oral iron?

A

If the patient has iron malabsorption, is intolerant of oral therapy, is non-compliant, etc.

6
Q

What symptoms would be observed in acute vs. chronic iron toxicity?

A

Acute: severe GI symptoms which can lead to shock and dyspnea. The child may appear to be improving, however, they still may progress to severe metabolic acidosis, coma and death.
It is almost always seen in children.

Chronic: hemochromatosis - iron deposits in the heart, liver, pancreas, etc. which leads to organ failure and death.

7
Q

What is the indication for parenteral Deferoxamine?

A

Acute iron toxicity; whole bowel irrigation is also indicated.

8
Q

What inactivated cyanocobalamin (a form of vitamin B12) during anesthesia?

A

Nitrous oxide

9
Q

What is the treatment for vitamin B12 deficiency (megaloblastic anemia and pernicious anemia)?

How does this change if neurological symptoms are present?

A

Oral vitamin B12 supplementation.

Parenteral therapy is indicated if neurological symptoms are apparent.

10
Q

What side-effect can occur with high dosage of folate?

A

Hypotension and hypoglycemia

11
Q

What happens if the body stores of vitamin B12 are depleted?

A

There is rapid onset of neurological dysfunction that may not fully reverse.

12
Q

How quickly do symptoms improve after treatment for megaloblastic anemia (folate vs. B12 treatment)?

How does this change if neurological symptoms are observed?

A

Typically they improve in a few days.

  • Hct increases in < 2 weeks with folate therapy and normalizes in about 2 mo.
  • Hb increases with 1 week of vitamin B12 therapy and should normalize in 1-2 mo.

If neurological symptoms are observed, it will take longer to improve and may not be reversible.

13
Q

Epoetin alfa MOA:

Indication:

Adverse-effect(s):

A

MOA: erythropoiesis-stimulating glycoprotein (stimulated erythropoiesis).

Indication: anemia due to chronic disease (CKD).

Adverse-effect(s): diastolic arterial pressure > 10 mmHg despite a Hct in 30-35% range.

14
Q

Hydroxyurea MOA:

Indication:

Adverse-effect(s):

A

MOA: targets ribonucleotide reductase and results in S-phase arrest. This lowers the [HbS] in the cell.

Indication: SSD - the only disease-modifying therapy for SSD.

Adverse-effect(s): cough, fever, chills, LBP, painful urination.

15
Q

Eculizumab MOA:

Indication:

Adverse-effect(s):

A

MOA: inhibits terminal complement-mediated intravascular hemolysis (binds C5 protein and prevents its cleavage).

Indication: paroxysmal nocturnal hemoglobinuria.

Adverse-effect(s): many - mostly infection (URI, HSV, flu, meningitis).

16
Q

Filgrastim MOA:

Indication:

Adverse-effect(s):

A

MOA: it is a synthetic G-CSF.

Indication: neutropenia.

Adverse-effect(s): allergic reactions (generally well-tolerated).

17
Q

What is the difference in Filgrastim and Sargramostin?

Which one has fever adverse-effects?

A

Filgrastim is a synthetic G-CSF.
Sargramostim is a synthetic GM-CSF.

Filgrastim.

18
Q

Plerixafor MOA:

Indication:

Adverse-effect(s):

A

MOA: partial agonist of CXCR4 receptor. This mobilizes HSCs from BM to plasma.

Indication: conditions where HSC mobilization is poor; also for lymphoma and MM.

Adverse-effect(s): hypersensitive reactions.

19
Q

Oprelvekin MOA:

Indication:

Adverse-effect(s):

A

MOA: recombinant for of IL-11 which increases platelet levels by promoting megakaryocyte maturation.

Indication: thrombocytopenia in patients undergoing myelosuppressive chemotherapy for non-myeloid cancers, but it does not have a major clinical use.

Adverse-effect(s): edema due to volume expansion, cardiac dysrhythmias and bloodshot eyes.

20
Q

What is the only orally available TPO receptor agonist?

A

Eltrombopag

21
Q

What is the 1st-line therapy for ITP?

What are 2nd/3rd-line treatments?

A

1st: splenectomy.

2nd/3rd: Romiplostim and Eltrombopag.
-they should be used if a splenectomy is contraindicated and/or rituximab did not work.

22
Q

What drugs most commonly cause hemolytic anemia? (2)

A

Cephalosporin antibiotics: ceftriaxone and cefotetan.

Piperacillin may also cause it.

23
Q

What drug causes immune drug-induced thrombocytopenia?

What drugs cause non-immune drug-induced thrombocytopenia?

A

Heparin

Quinidine and quinine.

24
Q

What can cause aplastic anemia? (3)

A

Cancer chemotherapies (esp. alkylation agents and cytotoxic antibiotics).

Chloramphenicol - antibiotic that is no longer used.

Benzene

25
Q

What is the only disease-modifying therapy for SSD?

A

Hydroxyurea

26
Q

What is the only drug indicated for PNH?

A

Eculizumab

27
Q

What drug “does not have a major clinical use”?

A

Oprelvekin